Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06108674

Telepharmacy on Patients With Arterial Hypertension

The goal of this clinical trial is to compare the effectiveness of a pharmaceutical care protocol via teleconsultation in the management of uncontrolled hypertension with pharmaceutical care carried out in elderly patients assisted in primary health care. The main questions it aims to answer are:

1. How effective is a pharmaceutical care protocol via teleconsultation on the clinical outcomes of elderly people with uncontrolled hypertension, when compared to in-person pharmaceutical care? 2. How effective is a pharmaceutical care protocol via teleconsultation in adherence to the treatment of elderly people with hypertension, when compared to in-person pharmaceutical care?

Participants will undergo four visits. Two visits will be for the application of instruments and measurement of clinical parameters to be carried out at the beginning and end of follow-up (visits 1 and 4). These will be carried out in a pharmacist's office at the pharmacy by previously trained pharmacists and pharmacy students. Visits 2 and 3 will be pharmaceutical consultations to be carried out in person and/or via telepharmacy.

Researchers will compare pharmaceutical care via telepharmacy with in-person pharmaceutical care to see how effective these services are in controlling blood pressure in elderly patients with uncontrolled blood pressure.

Recruiting

Interested in participating?

Request Info

Key information

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Farmácia Escola da UFBA, campus Anísio Teixeira

Vitória da Conquista, Estado de Bahia, 45028440, Brazil

Location status: Recruiting

Location contact

Marcio Galvão Oliveira, PhD

CONTACT

[email protected]

55 77 988280954

Márcio Galvão Oliveira, PhD

PRINCIPAL_INVESTIGATOR

About this study

Specific objectives

  • Characterize the clinical and socio-demographic profile of the studied population.
  • Compare the acceptance and clinical importance of interventions carried out by the pharmacist between the telepharmacy and in-person (control) groups.
  • Evaluate patient adherence to medication treatment in the teleconsultation group and in person
  • Evaluate patient satisfaction in the teleconsultation group and in-person consultation.
  • Compare satisfaction between the telepharmacy and in-person (control) groups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Elderly patients admitted to the service with a diagnosis of systemic arterial hypertension made by a physician based on a patient report, report or medical prescription.
  • Patients who present uncontrolled blood pressure at the time of assessment based on the average of three measurements using a standardized protocol at the pharmacy will be included;
  • Patients must have a cell phone and know how to use it;
  • Patient not have previously received pharmaceutical care.

Exclusion criteria

  • Elderly people who are unable to use their cell phones due to cognitive impairments (Mini Mental State Examination (MMSE).
  • Elderly person considered unable of using a telephone (Instrumental Activities of Daily Living)
  • Elderly with controlled blood pressure according to home monitoring.

Treatment and study plan

Pharmaceutical care via telepharmacy and usual care

Other

Pharmacotherapeutic monitoring via telephone consultation

Pharmaceutical care in-person and usual care

Other

Face-to-face pharmacotherapeutic monitoring

Primary outcomes

  1. Controlling blood pressure

    Time frame: 3 months

    Rate of patients reaching the blood pressure target for healthy elderly people: systolic pressure of 130-139 mmHg and diastolic pressure of 70-79 mmHg; and for frail elderly people: systolic pressure of 140-149 mmHg and diastolic pressure of 70-79mmHg according to guidelines from the Brazilian Society of Cardiology of 2020

Secondary outcomes

  1. Adherence to the treatment

    Time frame: 3 months

    Patients who score higher than eight points on the adherence scale will be considered to have high adherence, those who score between six and seven points will be classified as medium adherence and those who score less than 6 points will be classified as low adherence.

  2. Patient satisfaction

    Time frame: 3 months

    The score will be calculated by the sum of the user's answers divided by the number of corresponding questions. Thus, the closer to 5, the greater the satisfaction with the service and the closer to 1, the greater the dissatisfaction.

  3. Level of clinical significance of interventions

    Time frame: 3 months

    Clinical significance of the intervention as described by the DOCUMENT, which classifies interventions into four levels of clinical significance: low; light; moderate and high.

Study contacts

Contact information is provided by the study sponsor or research team.

Gabriella F Magalhães

CONTACT

[email protected]

77999062525

Sponsors and collaborators

Lead sponsor

Federal University of Bahia

Other

Registry information

Official study title

Evaluation of the Effectiveness of Telepharmacy on Clinical Outcomes of Patients With Arterial Hypertension: Celeste Randomized Clinical Trial

Acronym: CELESTE

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Oct 31, 2023
Registry last updated
Aug 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.